EUVIMEDEUVIMED entdecken
Open Access

Clinical Utility and Prognostic Implications of Circulating Cell-Free DNA in Biliary Tract Cancer

Darren Cowzer iD, Madison Darmofal, Kenneth Seier iD, Rohit Thummalapalli iD, Henry Walch iD, Imane El Dika, Danny N Khalil, Wungki Park iD, Aruj Dhyani, Amin Yaqubie, Paul Shin, Sepideh Gholami iD und 17 weitere

JCO Precision Oncology · 2025-09 · (9)

DOI: 10.1200/po-25-00355 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2025-09. Verfasst von Darren Cowzer und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Biliary Tract Neoplasms, Cell-Free Nucleic Acids. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE An estimated 25% of patients with biliary tract cancer (BTC) do not undergo genotyping, representing a missed opportunity for therapeutic targeting. METHODS Cell-free DNA (cfDNA) and matched tumor sample from patients with BTC were analyzed using targeted next-generation sequencing (NGS) assay and compared. We sought to define the molecular profile of cancer-derived cfDNA, frequency of OncoKB level 1/2 alterations, plasma:tumor genotype concordance, the prognostic impact of cfDNA, and clonal evolution after targeted therapy progression. RESULTS cfDNA-based genotyping was performed on 297 blood samples from 170 patients with BTC. The most frequently altered genes were TP53 (29%), FGFR2 (16%), ARID1A (13%), CDKN2A (11%), and KRAS (11%); 25% of patients had OncoKB level 1/2 alterations and 36.2% of potentially actionable alterations were detected in plasma alone. The cfDNA:tissue concordance accuracy was high (96% IDH1 , 98% BRAF , 92% KRAS mutations, 99% ERBB2 amplifications, and 96% FGFR2 fusions). Detectable tumor-derived cfDNA after resection did not predict recurrence. In treatment-naïve metastatic BTC, high variant allele fraction was associated with worse progression-free survival and overall survival. RAS alterations not detected in samples before treatment were identified at progression in 24% of patients who received BRAF-, FGFR-, or HER2-directed therapy, identifying RAS alterations as a convergent mechanism of targeted therapy resistance. CONCLUSION Molecular profiling of cfDNA from patients with BTC identified OncoKB level 1/2 gene alterations and putative genomic resistance mechanisms to targeted therapy. Concordance analysis suggests that cfDNA-based NGS is complementary to that of tissue-based sequencing in the identification of potentially actionable alterations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biliary Tract NeoplasmsCell-Free Nucleic AcidsHumansFemaleMaleMiddle AgedAgedPrognosisHigh-Throughput Nucleotide SequencingAged, 80 and overAdultBiomarkers, TumorGenotype

Substanzen

Cell-Free Nucleic AcidsBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Weill Medical College of Cornell University, New York, NY.
  • Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Saint John's Cancer Institute, Santa Monica, CA.
  • Northwell Health, New York, NY.

ORCID-Profile: Darren Cowzer, Kenneth Seier, Rohit Thummalapalli, Henry Walch, Wungki Park, Sepideh Gholami, Joseph Erinjeri, Alice C Wei, Randy Yeh, Richard K Do, Jinru Shia, Andrea Cercek, Alison Schram, Walid K Chatila, Nikolaus Schultz, Eileen M O'Reilly, Mithat Gonen, Michael F Berger, David B Solit, Ghassan K Abou-Alfa, William Jarnagin, James J Harding

Förderung

  • NCI NIH HHS

Zitieren

APA

Cowzer, D., Darmofal, M., Seier, K., Thummalapalli, R., Walch, H., El Dika, I., Khalil, D. N., Park, W., Dhyani, A., Yaqubie, A., Shin, P., Gholami, S., Erinjeri, J., Wei, A. C., Yeh, R., Do, R. K., Basturk, O., Shia, J., Cercek, A., …, & Harding, J. J. (2025). Clinical Utility and Prognostic Implications of Circulating Cell-Free DNA in Biliary Tract Cancer. JCO Precision Oncology. https://doi.org/10.1200/po-25-00355

Vancouver

Cowzer D, Darmofal M, Seier K, Thummalapalli R, Walch H, El Dika I, et al. Clinical Utility and Prognostic Implications of Circulating Cell-Free DNA in Biliary Tract Cancer. JCO Precision Oncology. 2025. doi:10.1200/po-25-00355

BibTeX
@article{Cowzer2025,
  author = {Cowzer, Darren and Darmofal, Madison and Seier, Kenneth and Thummalapalli, Rohit and Walch, Henry and El Dika, Imane and Khalil, Danny N and Park, Wungki and Dhyani, Aruj and Yaqubie, Amin and Shin, Paul and Gholami, Sepideh and Erinjeri, Joseph and Wei, Alice C and Yeh, Randy and Do, Richard K and Basturk, Olca and Shia, Jinru and Cercek, Andrea and Schram, Alison and Chatila, Walid K and Schultz, Nikolaus and O'Reilly, Eileen M and Gonen, Mithat and Berger, Michael F and Solit, David B and Abou-Alfa, Ghassan K and Jarnagin, William and Harding, James J},
  title = {Clinical Utility and Prognostic Implications of Circulating Cell-Free DNA in Biliary Tract Cancer},
  journal = {JCO Precision Oncology},
  year = {2025},
  number = {9},
  doi = {10.1200/po-25-00355}
}
Kostenlos starten →